NAS
SLS icon

Nykredit A/S’s SELLAS Life Sciences SLS Stock Holding History

Nykredit A/S’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.1K Buy
+1,839
New +$12.7K ﹤0.01% 1643

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 374.17% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nykredit A/S's SLS Position: Q2 2026 in Review

Nykredit A/S opened a new position in SELLAS Life Sciences (SLS) in Q2 2026: 1,839 shares worth $27.1K. The stake represents ﹤0.01% of the portfolio and ranks #1643 among its holdings.

144 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Nykredit A/S held 1,839 shares of SELLAS Life Sciences worth $27.1K as of Q2 2026.
  • SELLAS Life Sciences was a new Nykredit A/S position in Q2 2026.
  • SELLAS Life Sciences made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1643 holding.
  • 144 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.